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the medical records of the enrolled patients, prescriptions were analyzed. Relevant
patient information such as gender, age, and data concerning psychotropic pre-
scribing patterns such as type of medication, route of administration, dose and
frequency were collected and evaluated for prescription patterns and associated
pharmaceutical care. RESULTS: Among the 60 bipolar patients enrolled during the
study period from January 2011 to April 2011, majority of the patients (78.3%) were
prescribed with antipsychotics, with olanzapine (25%) and resperidone (23.3%) be-
ing the two most common drugs followed by sedatives (73.3%), with clonazepam
(38.3%) being the most common drug. A total of 68.3% of patients were prescribed
with Lithium as the most common mood stabilizer. Among the patients (43.3%)
prescribed with antidepressants, the combination of fluoxetin and amitriptyline
was most common (23.3%) followed by fluoxetin alone (11.6%).Only 9 patients (15%)
were prescribed with divalproex sodium, an anticonvulsant. CONCLUSIONS: This
study showed that antipsychotics and sedatives were the two most commonly
prescribed drugs in bipolar patients with lithium being the most widely prescribed
mood stabilizer. The quality of pharmaceutical care is highly variable among pa-
tients with bipolar disorders, even in a specialty treatment setting.
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OBJECTIVES: The aim of the study is to investigate the use of medications pre-
scribed to dementia patients in a secondary care hospital METHODS: A retrospec-
tive chart review method was performed in patients with diagnosis of dementia for
the duration of six months. The relevant information related to the study objec-
tives such as demographic details, type of medication, dose and frequency etc has
been collected. The patient who has come for follow up during the study period has
also been included to find out any outcomes RESULTS: Out of 30 patients included
in the study, 63.3% were females and 36.7% were males. Most of the patients belong
to the age group of 60-80 years. On prescription pattern analysis, it was found that
86.7% of the patients were on donepezil, cholinesterase inhibitors. Among antip-
sychotics Quetiapine was the most commonly used atypical antipsychotic. Five
(16.7%) patients were on memantine where as 4 (13.3%) patients were on combi-
nation of donepezil and memantine. On follow up it was found that in three pa-
tients who was on donepezil has been changed to a combination of donepezil and
memantine. Whereas in other two patients the dose of the donepezil has been
increased. As a result of improvement seen in two patients donepezil was stopped
and memantine was continued and in the other patient who has been on the
combination of donepezil and memantine has been tapered gradually and stopped
as there was a marked improvement seen. In this study, we could also find pre-
scription error in 13.33% (4) of the prescription related to the overdose of donepezil
CONCLUSIONS: In a developing country like India, dementia still remains as an
underrecognized public health burden. Our study depicts a picture of usage of
antidementia drugs, it shows that further research to be done in dementia patients
related to cost effectiveness
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OBJECTIVES: Driven by rising costs of health care and concern that much of this
spending could be reduced without detriment to health, comparative effectiveness
research (CER) has been offered as a means to identify what works and does not
work in health care. Little conceptual and empirical efforts have been made, how-
ever, to quantitatively assess the impact of CER on health and health care spend-
ing. We interpret CER as infusing publicly subsidized evidence on product quality
into health care markets, shifting the relative demand for products in CER studies.
We analyze how these shifts in demand affect health and health care spending,
allowing for the possibility that “winners” of CER may be both more demanded by
patients and doctors as well as more favorably covered by payers. We also analyze
how CER may either raise or lower overall health when treatments have heteroge-
neous effects across patients, but payers respond with product-specific coverage
policies. METHODS: We calibrate the effects of product-specific coverage policies
for a major CER study for antipsychotics, the CATIE trial. RESULTS: We find that
such policies would have led to a decrease in overall health and value by inducing
some patients to switch away from treatments that were effective for them to-
wards winners of the CER. CONCLUSIONS: Our overall conclusion is that CER may
not always have the intended effects when the market responds to the CER and
patient specific effects of treatments are present.
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OBJECTIVES: German HTA-Agency (IQWIG) has published its preliminary report
plan for Order G09-01 Cost-benefit analysis of venlafaxine, duloxetine, bupropion
and mirtazapine in comparison to other prescription drug treatments (version 1.0,
updated 05-09-2011). This report plan provides important indicators, on how and to
what extent innovative drugs are to be reimbursed by German statutory health
insurances (SHI). METHODS: IQWIG conducts a cost-benefit analysis that can be
divided into five steps with main focus on Mixed Treatment Comparison (MTC).
The individual steps in the cost-benefit analysis are largely dependent upon one
another, since the results of one step serve as the foundation for the next step of
the analysis. It is critical to note that IQWIG compares the four individual antide-
pressants to active agent categories such as serotonin reuptake inhibitors (SSRIs),
without having previously conducted a benefit analysis for these active agent
groups. RESULTS: Preliminary report with the provisional assessments is expected
in the 3rd quarter of 2011. At present, essential information and specifications of
the methodical approach are still missing. Each of these steps yields considerable
methodological challenges and can significantly influence the results of the cost-
benefit analysis. The MTC method, in particular, must be transparently described.
Only in this manner, will it be possible to prevent uncertainties after every step
from adding up to an invalid overall result. CONCLUSIONS: When MTC do not
present relevant differences, or present them inadequately, this has significant
effects on the assessment of therapeutic superiority, as well as on the appropriate-
ness of the costs within the scope of the cost-benefit analysis. The result of such a
cost-benefit analysis would be that the benefits and additional benefits of new
drugs are levelled and the price level for modern antidepressants is decreased for
Germany in future.
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OBJECTIVES: To apply innovative methods to observational data to explore vari-
ability in depression scores over 12 years and examine whether there are subsets of
individuals with different trajectories of change. METHODS: Latent Growth Mod-
eling (LGM) and Growth Mixture Modeling (GMM) analyses were applied to obser-
vational data collected over a 12-year period. Data was obtained from the RAND
version of the Health and Retirement Survey (HRS), consisting of N 5090 individ-
uals aged 51 - 61 years at the time of recruitment. Scores on an 8-item version of the
Center for Epidemiological Studies–Depression Scale (CES-D) were examined.
LGMs were conducted to determine the level of variability in depression scores over
the 12-year period. When considerable variability was identified, GMMs were con-
ducted to assess whether there were subsets of individuals with differential
changes. RESULTS: LGMs showed an intercept (first assessment point) score of 0.75
(“no depression”) on the CES-D, which increased to 1.3 (“sub-threshold depres-
sion”) at year 12. Substantial variability was found around the mean intercept and
slope of change. GMMs identified three subsets of individuals with differential
slopes of change. The largest subset (83% of the sample) had a mean intercept of
0.22 and a 12-year score of 1.0 (“no depression”). A smaller subset (13.7%) had a
mean intercept of 2.5 and showed no change over the 12-year period (“stable,
sub-threshold depressed”). The smallest subset (3.3%) had a high mean intercept
(6.0) and showed a decrease in depression scores (4.0 at year 12; “improved, actively
depressed”). Post hoc analyses showed that these three classes were significantly
different in terms of gender, self-reported health, whether health limits their work
or activities, and activities of daily living CONCLUSIONS: Examining highly vari-
able data can yield insights about subsets of respondents who show different levels
of initial depression and different trajectories of change.
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OBJECTIVES: To compare the utility values estimated from a disease-specific in-
strument with those obtained from the EQ5D and SF6D in a sample of patients
suffering from a psychotic disorder. METHODS: Data on patients diagnosed with
schizophrenia or bipolar disorders was gathered in a multicentre, cross-sectional
study. Patients completed both generic and specific measures: the TooL question-
naire, EQ-5D -VAS and TTO-, SF6D and the Clinical Global Impression -CGI-SI-. As it
has been recently published, a multi-attribute utility function (MAUF) for the Span-
ish version of the TooL questionnaire was estimated. Differences in utility scores
regarding CGI-SI- were tested with ANOVA and Kruskal-Wallis test. The Spearman
correlation coefficient (rho), intraclass correlation coefficient and Wilcoxon rank
test were calculated. Finally, the Bland-Altman method was followed for concor-
dance assessment. RESULTS: In total, 37 patients with schizophrenia and 33 with
bipolar disorder were assessed. Mean age (SD) was 41.88 (11.08), 62.9% were male
and CGI-SI- was: borderline-mildly (50%), moderately (35.7%) and markedly-ex-
tremely ill (13.3%). Significant differences according to CGI-SI were found in all
utility measures (p0.05). Although all associations were high (rho range: 0.657-
0.996), differences between the TooL scores and generic scales (SF6D and EQ5D;
p0.001) were found. Also between EQ5D and SF6D remarkable differences were
found (p0.001). Generic measures tended to overestimate at least 80% of health
states in comparison to the TooL values. Finally, a low concordance was detected,
even between generic measures. CONCLUSIONS: Although all measures of health
values are highly associated, a low concordance has been evidenced. Utility values
obtained from the TooL questionnaire could be used to complement the informa-
tion from the EQ5D or SF6D. Finally, the specific measure could be even considered
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to test the robustness of the incremental effectiveness in economical analysis
carried out in patients with schizophrenia or bipolar disorders.
PMH84
THE CORNELL-BROWN SCALE FOR QUALITY OF LIFE IN DEMENTIA: SPANISH
ADAPTATION AND VALIDATION
Lucas-Carrasco R1, Gomez-Benito J1, Rejas J2, Ott BR3
1University of Barcelona, Barcelona, Spain, 2Pfizer España, Alcobendas/Madrid, Spain, 3Warren
Alpert Medical School of Brown University, Providence, RI, USA
OBJECTIVES: The objective of this study was to culturally adapt and validate the
Cornell-Brown Scale (CBS) for Quality of Life (QoL) in Dementia into Spanish.
METHODS: The original CBS was translated into Spanish by mean of a conceptual
equivalence approach, including forward and backward translations in duplicate.
Subjects with mild-to-moderate dementia were recruited and interviewed by a
psychologist who was trained in administering questionnaires to obtain sociode-
mographic information, health perceptions, depressive symptoms (GDS-15), func-
tional ability (Barthel Index), dementia severity (MMSE), specific QoL (CBS) and
generic QoL (WHOQOL-BREF). Participants were included if they had a diagnosis of
dementia according to DSM-IV criteria, a MMSE scoring  9, were living at home,
and had a known and stable caregiver with whom were living or had daily contact.
Acceptability, reliability, and validity were assessed using standard psychometric
methods. Exploratory factor analysis (EFA) was applied to analyze the dimensional
structure of the scale for the first time. RESULTS: A total of 100 persons with
dementia (66% female; 79.18 years) were recruited: 61% Alzheimer’s disease; 17%
vascular dementia; 14% mixed dementia; and 8% other dementia. Internal consis-
tency reliability was good (Cronbach=s  0.87). A priori hypotheses about the
relationship between CBS and the WHOQOL-BREF psychological domain and
GDS-15 were confirmed, indicating good criteria validity; Pearson=s r 0.570 and
-0.537, respectively. Discriminant validity was confirmed by the ability of the scale
to significantly differentiate between healthy and unhealthy and depressed and
non-depressed participants; but not between mild and moderate dementia. The
EFA showed a five-factor solution which accounted for 63.9% of the total variance of
CBS. CONCLUSIONS: The Spanish version of CBS showed good psychometric prop-
erties of validity and reliability to explore QoL in patients with mild-to-moderate
dementia in Spain. The factor structure of the CBS is reported for the first time.
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OBJECTIVES: To compare the efficacy and safety of tumour necrosis factor alpha
(TNF) inhibitors in the treatment of active ankylosing spondylitis (AS), in adult
patients naïve to biologic therapy. METHODS: A literature search was performed,
first focused on identifying health technology assessment reports (HTAR), meta-
analysis and systematic reviews. The databases searched were MEDLINE, EMBASE,
CRD, and the Cochrane Library. An exhaustive search of randomized controlled
trials (RCTs) that compared directly the TNF-inhibitors was also carried out in
MEDLINE and EMBASE. Both searches covered until November 2010. Two authors
independently selected the studies, assessed the quality, and performed the data
extraction, with disagreements resolved by a third reviewer until consensus was
obtained. In addition, an analysis of adjusted indirect comparisons (AIC) against a
common comparator was done using the method of Bucher et al. and the software
from the Canadian Agency for Drugs and Technologies in Health version 1.0.
RESULTS: A HTAR was included, it compared the clinical efficacy of infliximab,
etanercept and adalimumab associated with conventional treatment versus con-
ventional treatment and it also compared TNF-inhibitors between them. Five RCTs
were included to update the report. One study directly compared infliximab and
etanercept and the other four RCTs evaluated each of the TNF-inhibitors (inflix-
imab, etanercept, adalimumab and golimumab) versus placebo. In the AIC analysis
performed considering all the evidence available, no statistically significant differ-
ences in the ASAS20 response between infliximab, etanercept, adalimumab and
golimumab were found. Also, there were no statistically significant differences
between the TNF-inhibitors in the rate of serious infections or withdrawals due to
adverse events. CONCLUSIONS: Only one RCT directly compares two TNF inhibi-
tors. Therefore, in the absence of such trials, AIC are considered. No clinically
relevant differences are observed in the efficacy and safety between infliximab,
etanercept, adalimumab and golimumab in the treatment of adult patients with
AS.
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OBJECTIVES: To evaluate the risk of infection and associated healthcare costs in
Rheumatoid Arthritis (RA) patients treated with anti-Tumor Necrosis Factor (anti-
TNF) therapy in Alberta, Canada. METHODS: RA patients initiating anti-TNF ther-
apy between January 2004 and March 2009 in Edmonton and Calgary were followed
prospectively to identify treatment efficacy and adverse events. Clinical and self-
reported data was linked with provincial healthcare administrative databases. In-
fections (any and severe) were identified by using ICD 9 and 10 diagnosis codes. We
used Cox-regression to assess the risk of infection and linear regression to assess
the associated costs. RESULTS: The cohort consists of 1,086 patients (70% female,
mean age of 54 years) with a mean follow-up of 2.3 years. Seventy percent of
patients (n764) reported an infection during follow-up, while 4% (n42) suffered
a severe infection. Compared to patients on their first anti-TNF (n731), patients
who switched to another anti-TNF (n212), patients on DMARD (n75), and pa-
tients switched from DMARD to anti-TNF (n68) had similar Hazard Ratios (HR)
(p0.05) for both any and severe infection. Pre-existing lung disease (HR1.98,
p0.001) and heart disease (HR1.42, p0.037) increased, while male sex (HR 0.79,
p0.005) decreased the risk of any infection. The risk of a severe infection was
increased by underlying anemia (HR3.20, p0.018) and in those with longer dis-
ease duration (HR1.03, p0.032), but was reduced in patients with university-
level education (HR0.34, p0.018), and osteoarthritis (HR0.37, p0.035). In linear
regression, Log(cost) was significantly associated with higher baseline HAQ score
and longer disease duration and in patients who required a switch between anti-
TNF agents for inefficacy or adverse events. CONCLUSIONS: The risk of any or
severe infection did not differ significantly between treatment groups. Some pre-
existing diseases increased while being male and having university education de-
creased the infection risk. Healthcare cost variations between the treatment
groups were small.
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OBJECTIVES: Osteoporosis is a disease with accelerated bone loss associated with
an increased risk of fractures. Histomorphometry of bone biopsy specimens from
postmenopausal women with osteoporosis measures bone remodeling activities
which include both bone formation and resorption. This study compared the ef-
fects of two osteoporosis treatments (20 g/day teriparatide vs. 10 mg/day alendro-
nate) on bone remodeling using the principal components analysis (PCA) of bone
histomorphometry parameters. METHODS: Postmenopausal women with osteo-
porosis treated with either teriparatide or alendronate and completed iliac crest
bone biopsy at either the sixth or eighteenth month in the randomized, double-
blind Forteo Alendronate Comparator Trial were included in the analysis (teripa-
ratide: N12; alendronate: N9). Eighteen histomorphometric parameters were
grouped into either the formation (13) or resorption (5) category. Within each cat-
egory, the first principal component was estimated through the PCA and defined as
the principal formation component (PFC) and principal resorption component
(PRC). The summation of PFC and PRC was calculated to represent the overall level
of bone turnover. The difference between PFC and PRC was computed to determine
the imbalance between formation and resorption. RESULTS:The PFC accounted for
61.8% of total variance in the 13 formation parameters, and the PRC accounted for
70.4% of total variance in the 5 resorption parameters. The PFC was significantly
higher in the teriparatide group than in the alendronate group (0.68 vs. -0.95,
p0.0001), while the PRC was significantly lower in the alendronate group (-0.47 vs.
0.32, p0.05). The difference between the PFC and PRC was positive in the teripa-
ratide group and negative in the alendronate group. CONCLUSIONS: In postmeno-
pausal women with osteoporosis, teriparatide treatment stimulates both bone for-
mation and resorption, and formation dominates resorption. Treatment with
alendronate suppresses both bone formation and resorption, and resorption dom-
inates formation.
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OBJECTIVES: The objective was to determine if the effectiveness of collagenase
clostridium histolyticum (XIAFLEX, CCH) in real-world settings is comparable to
the efficacy demonstrated in the clinical trials. METHODS: A retrospective chart
review was conducted at selected sites. Charts of each patient treated with CCH in
2010 were abstracted. Effectiveness results were compared to efficacy findings
from the clinical registration trial (CORD-I)1 on 1) final contracture angle, 2) change
in contracture, 3) final range of motion, and 4)change in range of motion, with
means of 12°, 38°, 81°, and 37° respectively. The equivalence range was set at /
10°.RESULTS: 501 patient charts were abstracted from 10 sites. The average patient
age was 65 years; 76% were male. The 95% confidence interval (C.I.) fell within the
corresponding predefined equivalence range of / 10° for each of the 4 effective-
ness measures (with means of 12°, 37°, 81°, and 37° respectively.) The effectiveness
injections/joint rate was 1.080.32(n629 joints) with a 95% C.I. of 1.05 to 1.11, This
CI does not fall within the reported C.I. of 1.6 to 1.8 in published trials (p0.05). The
average number of (injection, manipulation, and follow-up) office visits/injection
was 2.921.05 (n620). CONCLUSIONS: CCH effectiveness findings were equiva-
lent to those published for the CORD-I clinical trial, yet the effectiveness injections/
joint rate was 36% lower than in the trial. Visits per injection cycle were also lower
than in the published CORD-I trial. The number of CCH injections used in real-
world settings may be lower because a) both patient/physician knew that active
drug was administered; b) anesthesia was used at manipulation; c) patient focused
treatment outcomes were used without the strict requirements of a clinical trial
protocol.
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